97
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      scite_
       
      • Record: found
      • Abstract: found
      • Conference Proceedings: found
      Is Open Access

      The European research infrastructure for chemical biology and early drug discovery (EU-OPENSCREEN)

      Published
      conference-abstract
        1 ,
      RExPO24 Conference
      REPO4EU
      RExPO24
      3-5 July 2024
      Chemical Biology, Research Infrastructure, open access, FAIR data, early drug discovery, drug repurposing
      Bookmark

            Abstract

            The European research infrastructure initiative EU-OPENSCREEN 1 (www.eu-openscreen.eu) supports scientists to implement their early drug discovery projects on a collaborative basis. Through its more ca. 30 academic partner institutes across nine European countries, it offers complementary expertise and access to technology platforms for the development of novel chemical probes and early hit compounds for the life sciences community.

            Scientists who successfully applied to implement their discovery projects with EU-OPENSCREEN transfer their assays to one of EU-OPENSCREEN screening partner sites. All partner sites jointly use a unique diversity compound collection containing ca. 100,000 commercial compounds and a growing collection of compounds that have been submitted by chemists from all over Europe. The partner sites have a track record of compound screening campaigns across a wide range of formats, including biochemical, cell-based, and model organism-based screens. Specialist screening sites complement larger high-capacity screening sites by offering specialised expertise and technologies that are not commonly available at the high-capacity screening facilities (e.g., BSL3 capacities). The primary screening data (including data of inactive compounds) are made available to the scientific community via its open-access European Chemical Biology Database (https://ecbd.eu/). Post-screening, EU-OPENSCREEN's medicinal chemistry partner sites support the hit-to-lead optimisation to improve the potency, selectivity, and in vitro/in vivo ADMET properties of the identified compounds. Confirmation of drug mechanism of action and target engagement studies are supported by our chemoproteomics sites and can be realised via close collaborations with structural biology partners in the INSTRUCT community

            Compound repurposing is an important strategy for the identification of effective drugs. EU-OPENSCREEN designed a compound collection of 2,464 known bioactives with high target selectivity against 1,039 different targets. This bioactives collection contains 654 approved drugs and 368 highly selective probes from the public domain. In addition, various drug repurposing collections are available for drug repurposing studies at our partner sites, including the most comprehensive and up-to-date biologically annotated collections of FDA-approved compounds based on the Drug Repurposing Hub 2 and ReFRAME 3 library.

            Content

            Author and article information

            Conference
            RExPO24 Conference
            REPO4EU
            3 May 2024
            Affiliations
            [1 ] EU-OPENSCREEN;
            Author notes
            Author information
            https://orcid.org/0000-0003-2759-5924
            Article
            10.58647/REXPO.24000048.v1
            d8081816-2dc5-4652-9bc9-dc6bfbd3dc1d

            This work has been published open access under Creative Commons Attribution License CC BY 4.0 , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Conditions, terms of use and publishing policy can be found at www.scienceopen.com .

            RExPO24
            3
            Munich, Germany
            3-5 July 2024
            History
            : 3 May 2024
            Categories

            Data sharing not applicable to this article as no datasets were generated or analysed during the current study.
            Biochemistry,Pharmaceutical chemistry
            Chemical Biology,Research Infrastructure,open access,FAIR data,early drug discovery,drug repurposing

            Comments

            Comment on this article